Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:EMISNASDAQ:FIXXNASDAQ:PRVBNASDAQ:RAPTNASDAQ:SYRS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFIXXHomology Medicines$0.93+0.8%$0.51$0.46▼$1.48$54.33M-0.1390,307 shs401,400 shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsRAPTRAPT Therapeutics$8.03+2.2%$10.28$6.86▼$27.35$279.44M0.471.17 million shs155,505 shsSYRSSyros Pharmaceuticals$5.15+3.2%$6.20$2.09▼$8.17$137.66M1.75215,630 shs113,779 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FIXXHomology Medicines0.00%0.00%+0.77%+216.85%+90.76%PRVBProvention Bio0.00%0.00%0.00%0.00%+2.71%RAPTRAPT Therapeutics-1.13%-7.96%-5.64%-68.76%-60.22%SYRSSyros Pharmaceuticals+9.91%-6.73%-20.41%-23.23%+86.89%Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFIXXHomology Medicines0.4475 of 5 stars1.30.00.04.80.00.81.3PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/ARAPTRAPT Therapeutics4.3522 of 5 stars4.34.00.03.61.41.70.6SYRSSyros Pharmaceuticals3.9753 of 5 stars3.51.00.04.32.23.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMISEmisphere TechnologiesN/AN/AN/AN/AFIXXHomology Medicines2.50Moderate Buy$0.75-19.76% DownsidePRVBProvention BioN/AN/AN/AN/ARAPTRAPT Therapeutics2.50Moderate Buy$25.67219.63% UpsideSYRSSyros Pharmaceuticals3.00Buy$14.33178.32% UpsideCurrent Analyst RatingsLatest SYRS, PRVB, FIXX, EMIS, and RAPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral4/3/2024SYRSSyros PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.004/1/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/21/2024RAPTRAPT TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$35.00 ➝ $13.002/21/2024RAPTRAPT TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $15.002/21/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/20/2024RAPTRAPT TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AFIXXHomology Medicines$1.16M46.84N/AN/A$1.26 per share0.74PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84RAPTRAPT Therapeutics$1.53M182.64N/AN/A$4.27 per share1.88SYRSSyros Pharmaceuticals$9.94M13.85N/AN/A$0.79 per share6.52Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%5/9/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ARAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$5.76N/AN/AN/A-1,656.34%-227.91%-75.60%5/8/2024 (Estimated)Latest SYRS, PRVB, FIXX, EMIS, and RAPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMISEmisphere TechnologiesN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMISEmisphere TechnologiesN/AN/AN/AFIXXHomology MedicinesN/A7.257.25PRVBProvention Bio0.191.931.92RAPTRAPT TherapeuticsN/A7.417.41SYRSSyros Pharmaceuticals2.073.953.95OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMISEmisphere TechnologiesN/AFIXXHomology Medicines31.32%PRVBProvention Bio37.39%RAPTRAPT Therapeutics99.09%SYRSSyros Pharmaceuticals91.47%Insider OwnershipCompanyInsider OwnershipEMISEmisphere Technologies72.90%FIXXHomology Medicines16.10%PRVBProvention Bio13.10%RAPTRAPT Therapeutics6.60%SYRSSyros Pharmaceuticals10.45%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMISEmisphere Technologies6N/AN/ANot OptionableFIXXHomology Medicines758.13 million48.77 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableRAPTRAPT Therapeutics13134.80 million32.50 millionOptionableSYRSSyros Pharmaceuticals6826.73 million23.94 millionOptionableSYRS, PRVB, FIXX, EMIS, and RAPT HeadlinesSourceHeadlineSyros Pharmaceuticals (NASDAQ:SYRS) Downgraded to Sell at StockNews.comamericanbankingnews.com - April 18 at 5:56 AMSyros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.commarketbeat.com - April 17 at 11:13 PMSyros Pharmaceuticals (NASDAQ:SYRS) Stock Passes Below 50-Day Moving Average of $6.38americanbankingnews.com - April 17 at 5:08 AMSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for Tamibarotenemarketwatch.com - April 10 at 5:56 PMSyros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AMLzacks.com - April 10 at 10:50 AMSyros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?zacks.com - April 10 at 9:31 AMSyros jumps on FDA fast track tag for leukemia drugmsn.com - April 9 at 3:57 PMFast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid Leukemiamarkets.businessinsider.com - April 9 at 10:45 AMSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionbusinesswire.com - April 9 at 7:00 AMSyros Pharmaceuticals (NASDAQ:SYRS) Receives Overweight Rating from Piper Sandlermarketbeat.com - April 3 at 12:14 PMSyros Pharmaceuticals, Inc. Expected to Earn Q1 2024 Earnings of ($1.20) Per Share (NASDAQ:SYRS)marketbeat.com - April 3 at 6:00 AMSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 2 at 4:30 PMSyros Pharmaceuticals (NASDAQ:SYRS) Receives "Buy" Rating from HC Wainwrightmarketbeat.com - April 1 at 8:22 AMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 31.8% in Marchmarketbeat.com - March 30 at 12:39 PMSyros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 29 at 11:42 PMEarnings call: Syros Pharmaceuticals strong Q4 and full year financialsinvesting.com - March 29 at 11:42 PMSyros Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, Brookline Capital Management Forecasts (NASDAQ:SYRS)marketbeat.com - March 29 at 8:15 AMSyros Pharmaceuticals (NASDAQ:SYRS) Upgraded to Hold by StockNews.commarketbeat.com - March 28 at 11:15 PMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 28 at 12:38 PMAnalysts Issue Forecasts for Syros Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:SYRS)marketbeat.com - March 28 at 8:59 AMSyros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene Trialsmarkets.businessinsider.com - March 28 at 7:37 AMSyros Pharmaceuticals Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 28 at 7:37 AMSyros Pharmaceuticals earnings preview: what Wall Street is expectingmarkets.businessinsider.com - March 27 at 4:30 PMSYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 27 at 12:05 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEmisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Homology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanySyros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.